• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Federico Moscardó, Faustino Pérez, +6 authors Miguel Angel Muńoz Sanz
  • Medicine
  • British journal of haematology
  • 2001 (First Publication: 1 July 2001)
  • Recombinant activated factor VII (rFVIIa) is indicated mainly for the treatment of patients with haemophilia and inhibitors. However, little information is available on the use of rFVIIa in theContinue Reading
  • Albert Oriol, Susana Vives, +17 authors Josep‐María Ribera
  • Medicine
  • Haematologica
  • 2010 (First Publication: 1 April 2010)
  • BACKGROUND About one half of adults with acute lymphoblastic leukemia are not cured of the disease and ultimately die. The objective of this study was to explore the factors influencing the outcomeContinue Reading
  • Jaime Sanz, Marcos Arango, +14 authors Guillermo F. Sanz
  • Medicine
  • Bone Marrow Transplantation
  • 2014 (First Publication: 1 March 2014)
  • We analyzed the incidence, clinicopathological features, risk factors and prognosis of patients with EBV-associated post-transplant lymphoproliferative disorder (EBV-PTLD) in 288 adults undergoingContinue Reading
  • Jaime Beltrán Sanz, Isabel Palazon Cano, +14 authors Guillermo F. Sanz
  • Medicine
  • Biology of blood and marrow transplantation…
  • 2015 (First Publication: 1 April 2015)
  • The incidence, epidemiology, and risk factors of bloodstream infection (BSI) and their impact on transplant outcomes after umbilical cord blood transplantation (UCBT) are not well defined. BetweenContinue Reading
  • Eva Barragán, Juan C. Pajuelo, +7 authors Pascual Bolufer
  • Biology, Medicine
  • Clinica chimica acta; international journal of…
  • 2008 (First Publication: 1 September 2008)
  • BACKGROUND Molecular analysis of minimal residual disease is only applicable in acute myeloblastic leukemia (AML) patients with genetic markers (20-30%). This study analyzes the feasibility of theContinue Reading